Prothea Technologies Ltd. Company Research Report

Company Overview

Name and Mission

Name: Prothea Technologies Ltd.

Mission: To innovate lung cancer diagnosis and treatment by offering biopsy and treatment in a single hospital visit, thus reducing time-to-treat from weeks to minutes, alleviating hospital pressures, and improving patient outcomes.

Founding Details

Founded: No information is available on the specific year of founding.

Founders: No information is available on the specific founders.

Key People

CEO: Crispin Simon, formerly of Smith and Nephew’s Endoscopy Division.

CSO/CMO: Prof. Kev Dhaliwal, Professor of Molecular Imaging & Healthcare Technology at the Royal Infirmary of Edinburgh.

Board of Directors:

Charles Carignan, MD

Peter Stratford

Dr. John Yianni, representing Earlybird Venture Capital

Dr. Yoann Bonnamour, representing Merieux Equity Partners

Dr. Thomas Raueiser, representing NRW.BANK

Headquarters

Location: Edinburgh, Scotland

Number of Employees

No information is available.

Revenue

No information is available.

Core Competencies

Prothea is particularly known for its focus on real-time imaging and interventional treatment technologies in lung cancer therapy.

Products

Product Offerings

Medical Device: An advanced system combining a Microendoscope with an Image Processing System.

Description: This device enhances visualisation by providing in situ analysis of lesion structures at the molecular level alongside biopsy tools, with plans for integration with a laser ablation catheter for immediate treatment after biopsy.

Key Features:

Real-time imaging.

In situ analysis of molecular structures.

Future integration with laser ablation catheter.

Potential integration with robotic surgery systems and other imaging modalities, enhanced by artificial intelligence.

Recent Developments

Series A Launch: On April 9, 2024, Prothea Technologies launched with a €12M Series A funding round. Key investors include Earlybird Venture Capital and Merieux Equity Partners.

New Products

No information is available about any new product launches.

New Features

Development: Further research and development are aimed at integrating the Imaging Processing System with laser ablation and possibly enhancing other medical imaging modalities.

Partnerships

Investors and Collaborators:

Supported by Earlybird Venture Capital, Merieux Equity Partners, NRW.BANK, and Old College Capital.

Collaborative ties with Universities of Edinburgh and Bath with technology developments funded by UK Research and Innovation, the Wellcome Trust, CARB-X, and Cancer Research UK.

Contact Information

COO/CFO Email: anne.moore@prothea.tech

Privacy Contact: privacy@prothea.tech

Conclusion

Prothea Technologies Ltd. is positioned as an innovator in the field of lung cancer treatment through its cutting-edge medical devices and strategic partnerships. With significant Series A funding, it aims to pioneer new technologies that improve early diagnosis and treatment options.

(End of Report)